Adaptive Radiotherapy in Head and Neck Tumor Patients

Launched by UNIVERSITY HOSPITAL, ESSEN · Jan 19, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new type of radiation therapy called dysphagia-optimized intensity-modulated radiotherapy (DO-IMRT) for patients with cancers in the throat, specifically oropharyngeal and hypopharyngeal cancers. The goal is to see if this method can reduce radiation exposure to areas that affect swallowing while still treating the cancer effectively. By doing this, researchers hope to improve patients' ability to swallow and their overall quality of life compared to standard radiation therapy.

To participate in this trial, patients should be between the ages of 65 and 74, have a good performance status (meaning they can carry out daily activities), and should not have received prior cancer treatment. Participants can expect to receive either the new DO-IMRT or the standard treatment, with the chance to help improve future care for others with similar conditions. This study is still recruiting participants, and it aims to set a new standard for how we treat pharyngeal cancer while minimizing side effects like difficulty swallowing.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • ECOG 0/1 No prior cancer treatment
• Exclusion Criteria:
• • ECOG 2-4 Prior cancer treatment